AMI Asset Management Corp Cuts Stake in Zoetis Inc. $ZTS

AMI Asset Management Corp reduced its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 5.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 314,239 shares of the company's stock after selling 16,887 shares during the quarter. Zoetis comprises approximately 2.8% of AMI Asset Management Corp's investment portfolio, making the stock its 14th biggest holding. AMI Asset Management Corp owned about 0.07% of Zoetis worth $49,006,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in ZTS. Nova Wealth Management Inc. purchased a new stake in shares of Zoetis during the first quarter valued at $25,000. 1248 Management LLC purchased a new stake in shares of Zoetis during the first quarter valued at $27,000. Saudi Central Bank purchased a new stake in shares of Zoetis during the first quarter valued at $29,000. Cornerstone Planning Group LLC grew its holdings in shares of Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after buying an additional 88 shares during the last quarter. Finally, ORG Partners LLC grew its holdings in shares of Zoetis by 56.8% during the second quarter. ORG Partners LLC now owns 232 shares of the company's stock valued at $37,000 after buying an additional 84 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and decreased their target price for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Piper Sandler boosted their target price on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Argus restated a "buy" rating and set a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Finally, Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Zoetis has a consensus rating of "Moderate Buy" and an average price target of $200.88.

Zoetis Trading Up 0.4%

Shares of Zoetis stock opened at $146.87 on Thursday. The firm has a 50-day simple moving average of $150.02 and a two-hundred day simple moving average of $155.39. The company has a market cap of $65.09 billion, a P/E ratio of 25.28, a price-to-earnings-growth ratio of 2.35 and a beta of 0.90. Zoetis Inc. has a fifty-two week low of $139.34 and a fifty-two week high of $196.55. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company's revenue was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.